 | | |
| |
|
| |
|
Appointments
|
|
Associate Attending Pathologist
|
|
Associate Professor of Pathology and Laboratory Medicine
|
|
|
|
|
| |
Wang, Lynn
 (212) 746-6402  (212) 746-8345
Dr. Y. Lynn Wang serves as the Director of the Molecular Hematopathology Laboratory at Weill Cornell. This CLIA-certified and CAP-accredited clinical laboratory offers PCR-based testing for molecular genetic lesions in lymphomas and leukemias to aid in diagnosis and therapeutic monitoring. Research in her clinical laboratory focuses on new molecular test development and optimization (Diag Mol Path. 14,17-22, 2005; J. Mol. Diagn. 8, 231-9, 2006; J. Mol. Diagn. 8, 385-9, 2006; J. Mol. Diagn. 9, 272-6, 2007). The lab also performs research, in collaboration with hematologists/oncologists, that helps define and explore the clinical utilities of these new tests (Acta Haematol. 118, 209-14, 2007; Leukemia. 22, 1289, 2008). In addition, Dr. Wang is an active member of the International BCR-ABL RQ-PCR Standardization Group that conducts research and makes recommendations for the clinical laboratory practice of CML molecular monitoring (Blood, 108, 28-37, 2006; Blood, 112, 3330-8, 2008).
Besides clinical service/administration and clinical laboratory research, Dr. Wang also acts as the principal investigator of a translational research laboratory. The lab focuses on aberrant signal transduction in lymphomas and leukemias, as well as the utilization of the derived information to develop molecularly targeted therapies. A variety of molecular, cellular, immunological, biochemical, and pharmacological approaches are utilized to determine the contribution of particular signaling cascades in the pathogenesis of hematological malignancies (J. Immunol. 177, 3737-45, 2006; Am. J. Pathol. 170, 722-32, 2007; PPAR Research, v2008, 1-13, 2008; Leukemia. 22, 1755-66, 2008). Currently, a number of projects aim to understand the role of B-cell receptor (BCR) signaling in lymphoma cell survival and proliferation. A recent study from the lab showed that dasatinib, a SRC tyrosine kinase inhibitor, interferes with BCR signaling and causes cell cycle arrest in diffuse large B cell lymphoma (DLBCL). The data not only suggests dasatinib as a potentially useful therapy for DLBCL, but also demonstrates the critical role of BCR signaling in lymphoma cell proliferation. Moreover, potential biomarkers are identified by this study to predict dasatinib therapeutic response (Leukemia, 22, 1755-66, 2008). Based on these promising preclinical data, a phase II clinical trial that integrates the identified biomarkers has been developed to test the efficacy of dasatinib in lymphoma patients. Several other projects on AIDS-related lymphomas, CLL, and AML are ongoing, many of which are conducted in collaboration with other scientists, pathologists and heme/onc physicians at Weill Cornell and other institutions.
|
| |
|
| |
|
| |
|
|
|
| |
|
| Medical
Practice(s) |
Visit this physician's medical practice site for information
on: - Making an Appointment
- Office Hours
- Office Staff
- Directions
|
|
| |
| |
|
|
|
| Clinical
Expertise |
|
Molecular Hematopathology
|
|
Clinical Pathology
|
|
Laboratory Medicine
|
|
|
|
| |
| |
|
| |
|
| Education |
|
Ph.D., Brandeis University, 1996
|
|
M.D., University of the State of New York, 2002
|
|
|
|
| |
| |
|
| |
|
Back to Top